Stockscreener 앱 받기
33.36
8.98%
-3.29
시장 영업 전:
33.40
0.04
+0.12%
전일 마감가:
$36.65
열려 있는:
$36.65
하루 거래량:
607.65K
Relative Volume:
1.57
시가총액:
$1.02B
수익:
$339.92M
순이익/손실:
$-12.83M
주가수익비율:
-77.67
EPS:
-0.4295
순현금흐름:
$4.52M
1주 성능:
-4.36%
1개월 성능:
+1.37%
6개월 성능:
+34.90%
1년 성능:
+43.11%
1일 변동 폭
$33.10
$37.99
1주일 범위
$33.10
$37.99
52주 변동 폭
$17.72
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
33.36 | 1.09B | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Bank of America Corp DE Makes New $2.35 Million Investment in Castle Biosciences, Inc. $CSTL - MarketBeat
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years. - Stock Titan
Castle Biosciences (CSTL) Study Validates TissueCypher Test's Im - GuruFocus
A test changed doctors’ plans for 90% of patients with the same precancerous esophagus condition. Their risks differed. - Stock Titan
Castle Biosciences CEO sells $512k in stock - Investing.com
Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com Nigeria
Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Texas bioscience firm expands in Scottsdale as AZ headcount tops 200 - The Business Journals
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ - PR Newswire
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 8,580 Shares - MarketBeat
CSTL Looks 17.2% Overvalued on GF Value™ as Market Prices in Str - GuruFocus
Castle Biosciences opens 55,000 sq ft Arizona lab facility By Investing.com - Investing.com Canada
Castle Biosciences to Open New Lab in Arizona - marketscreener.com
Castle Biosciences opens 55,000 sq ft Arizona lab facility - Investing.com
Castle Biosciences,Opens New Laboratory And Office Facility In Scottsdale, Arizona - TradingView
Castle Biosciences to Open New Laboratory Facility in Scottsdale - PR Newswire
Castle Biosciences (CSTL) Insider Trading Activity 2026 $CSTL - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: A 19.63% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Castle Biosciences Inc (CSTL) Shares Surge 3.7% -- What GF Score of 82 Tells Investors - GuruFocus
Castle Biosciences (NASDAQ: CSTL) Chief Commercial Officer Juvenal Tobin W Sells 6,600 Shares Between $32.32 and $35.14 - Kalkine Media
Castle Biosciences Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock GainEstimate Uncertainty - siam.in
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,600 Shares - GuruFocus
Tobin Juvenal Sells 3,306 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - marketbeat.com
Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,294 Shares of Stock - MarketBeat
6,600 Castle Biosciences (CSTL) shares sold under preset 10b5-1 plan - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Shares Up 4.3%Here's What Happened - MarketBeat
Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management - Yahoo Finance
CSTL Looks 12.1% Overvalued on GF Value™ - GuruFocus
A study found a test could nearly double closer monitoring or treatment for some Barrett’s patients - Stock Titan
Castle Biosciences (CSTL) CCO plans more stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Preset sale plan at Castle Biosciences (CSTL) covers 29K shares - Stock Titan
Castle Biosciences, Inc.JAAD Publication Shows Improved Performance of DecisionDx-SCC - marketscreener.com
Responsive Playbooks and the CSTL Inflection - Stock Traders Daily
Castle Biosciences, Inc. (CSTL) Stock Price Quote Today & Current Price Chart - Capital.com
JAAD Publication Shows Improved Performance of DecisionDx®-SCC - STLtoday.com
SciBase receives additional order from Castle Biosciences, advancing the collaboration - Yahoo Finance
Bank of New York Mellon Corp Invests $2.34 Million in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Stock Price Forecast. Should You Buy CSTL? - StockInvest.us
Castle Biosciences Inc. (CSTL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE - MarketBeat
Castle Biosciences COO Oelschlager sells $138,642 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences COO Oelschlager sells $138,642 in shares - investing.com
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares By Investing.com - Investing.com South Africa
Castle Biosciences (NASDAQ:CSTL) Beats Estimates As Momentum Builds - Kalkine Media
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 1,730 Shares - GuruFocus
Castle Biosciences (CSTL) Slips 2.4% to $32.62: Key Support in FocusNews Sentiment - vinanet.vn
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares - Investing.com
Empowered Funds LLC Acquires New Shares in Castle Biosciences, Inc. $CSTL - marketbeat.com
Castle Biosciences (NASDAQ: CSTL) CCO sells 1,730 shares under 10b5-1 plan - Stock Titan
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Castle Biosciences Inc 주식 (CSTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Juvenal Tobin W | Chief Commercial Officer |
Sep 29 '26 |
Sale |
35.50 |
5,543 |
196,765 |
53,041 |
| Juvenal Tobin W | Chief Commercial Officer |
Sep 30 '26 |
Sale |
34.20 |
1,034 |
35,363 |
52,007 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 21 '26 |
Option Exercise |
2.39 |
8,580 |
20,506 |
30,059 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 21 '26 |
Sale |
35.33 |
8,580 |
303,166 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 21 '26 |
Sale |
35.33 |
5,916 |
209,036 |
9,550 |
| Juvenal Tobin W | Chief Commercial Officer |
Sep 15 '26 |
Sale |
35.14 |
3,294 |
115,758 |
58,584 |
| Juvenal Tobin W | Chief Commercial Officer |
Sep 14 '26 |
Sale |
32.32 |
3,306 |
106,863 |
61,878 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Option Exercise |
2.39 |
8,584 |
20,516 |
30,063 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Sale |
32.02 |
8,584 |
274,862 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Sep 11 '26 |
Sale |
32.02 |
5,934 |
190,008 |
12,268 |
0.99%
0.56%
자본화:
|
볼륨(24시간):